European Journal of Heart Failure

Article	Citations
Epidemiology of heart failure	718
Myocardial localization of coronavirus in COVID‐19 cardiogenic shock	691
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	516
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Soci	428
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐O	275
Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis	235
Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)	211
Epidemiology, pathophysiology and contemporary management of cardiogenic shock – a position statement from the Heart Failure Association of the European Society of Cardiology	189
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), th	180
COVID‐19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease	174
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rational	173
Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology	172
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardio	159
Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications	154
Changes in m6A RNA methylation contribute to heart failure progression by modulating translation	154
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial	152
The impact of COVID‐19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic	143
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and	141
Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012–2015	141
Phenomapping of patients with heart failure with preserved ejection fraction using machine learning‐based unsupervised cluster analysis	133
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology	131
Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology	128
Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years	123
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial	118
Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure	118

Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta‐analysis	116
Pulmonary artery pressure‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart F	116
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure	116
Lung ultrasound‐guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS‐HF study)	111
Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust	109
Improving risk prediction in heart failure using machine learning	108
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019	97
Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE‐HF cohort study	96
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology	94
Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity	93
Management of heart failure patients with COVID‐19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association	91
Circulating cardiovascular microRNAs in critically ill COVID‐19 patients	91
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study	89
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care	87
Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies	86
Validation of the HFA‐PEFF score for the diagnosis of heart failure with preserved ejection fraction	84
Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction	83
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatme	81
Endothelium‐dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction	81
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study	80
Temporal trends in decompensated heart failure and outcomes during COVID‐19: a multisite report from heart failure referral centres in London	78
Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF	76
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial	76
Depression and heart failure: the lonely comorbidity	75
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy	74
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper	73
Hypertrophic cardiomyopathy: the future of treatment	72
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction	72
Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implan	70
An expert consensus document on the management of cardiovascular manifestations of Fabry disease	69
Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long	69
Light‐chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome	68
Association of COVID‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection	67
Selenium and outcome in heart failure	66
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA)	66
Haemodynamic characteristics of COVID‐19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization	65
Bone marrow‐derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4‐year follow‐up of the MSC‐HF trial	65
Telemonitoring versus standard care in heart failure: a randomised multicentre trial	64
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study	64
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure	64
Trends in cardiogenic shock complicating acute myocardial infarction	63
The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE	63
Ultrasound imaging of congestion in heart failure: examinations beyond the heart	63
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)	62
Myocardial adipose deposition and the development of heart failure with preserved ejection fraction	62
Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors	61
Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta‐analysis	61
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure	61
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF	60
Heart failure management during the COVID‐19 outbreak in Italy: a telemedicine experience from a heart failure university tertiary referral centre	60

Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction	60
Sex‐ and age‐related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long‐Term Registry	59
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis	59
Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient‐level database analysis	59
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial	59
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review	59
Regional adiposity and heart failure with preserved ejection fraction	58
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis	58
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction	57
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure	57
Pulmonary artery pulsatility index: physiological basis and clinical application	56
Characterization of NT‐proBNP in a large cohort of COVID‐19 patients	55
Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial	55
Cachexia, muscle wasting, and frailty in cardiovascular disease	55
The impact of residual mitral regurgitation after MitraClip therapy in functional mitral regurgitation	54
Caring for people with heart failure and many other medical problems through and beyond the COVID‐19 pandemic: the advantages of universal access to home telemonitoring	54
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction	53
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics	53
Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials	52
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial	51
Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients	50
Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction	50
Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta‐regression in the past four decades	50
Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRA	49
Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure	48
Trends in prevalence of comorbidities in heart failure clinical trials	48
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction	47
Sex‐related differences in contemporary biomarkers for heart failure: a review	47
Readmission and death in patients admitted with new‐onset versus worsening of chronic heart failure: insights from a nationwide cohort	47
The cancer patient and cardiology	47
Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first‐in‐human study	46
Clinical importance of urinary sodium excretion in acute heart failure	46
Ejection fraction and mortality: a nationwide register‐based cohort study of 499 153 women and men	45
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subje	45
In‐hospital care in acute heart failure during the COVID‐19 pandemic: insights from the German‐wide Helios hospital network	45
Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high‐risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European So	44
Haemodynamic and metabolic phenotyping of hypertensive patients with and without heart failure by combining cardiopulmonary and echocardiographic stress test	44
Decreases in acute heart failure hospitalizations during COVID‐19	44
Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy?	44
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC	44
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy	43
Long‐term follow‐up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co‐morbidities	43
The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy	42
Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment	41
Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction	41
Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy	41
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial	41
Contemporary survival trends and aetiological characterization in non‐ischaemic dilated cardiomyopathy	40
Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and	40
Effect of dapagliflozin on anaemia in DAPA‐HF	40
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology	39
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review	39
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials	39
Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo‐controlled trial	39
Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐d	39
Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology	38
Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis	37
Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart	37
A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF‐HFpEF	37
OUTSTEP‐HF: randomised controlled trial comparing short‐term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fr	37
SARS‐CoV‐2‐related myocarditis‐like syndromes Shakespeare's question: what's in a name?	37
High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality	36
Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and r	36
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Regist	35
Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo‐controlled, non‐inferiority ARIES HM3 trial	35
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐m	35
The impact of palliative care on clinical and patient‐centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials	35
Less invasive ventricular reconstruction for ischaemic heart failure	35
Assessing the evidence–practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics	34
A randomised, double‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes	34
One‐year results of the first‐in‐man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study	34
Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug treatments for patients with a reduced ejec	34
Recovery of cardiac function following COVID‐19 – ECHOVID‐19: a prospective longitudinal cohort study	33
Left atrial structure and function and the risk of death or heart failure in atrial fibrillation	33
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey	32
Mitral regurgitation, left atrial structural and functional remodelling and the effect on pulmonary haemodynamics	32
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI	32
Virtual optimization of guideline‐directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT‐HF pilot study	32
Urinary peptides in heart failure: a link to molecular pathophysiology	31
Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry	31

Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies	31
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology	31
Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence	31
MiRNA‐181a is a novel regulator of aldosterone–mineralocorticoid receptor‐mediated cardiac remodelling	30
Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial	29
Long‐term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system	29
Clinical value of pre‐discharge bio‐adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission	29
The combination of carboxy‐terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic	29
Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM‐HF) study	29
A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure	28
Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF	28
Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial	28
Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction	28
Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC‐EORP Heart Failure Long‐Term Registry	28
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the Eu	28
Serum potassium in the PARADIGM‐HF trial	28
Pathogenesis and management of myocardial injury in coronavirus disease 2019	28
Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first‐in‐human clinical trial	28
Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology	28
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction	28
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial	28
Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure	28
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations	27
Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhib	27
Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and Eu	27
Long‐term survivors of early breast cancer treated with chemotherapy are characterized by a pro‐inflammatory biomarker profile compared to matched controls	27
Cardiac iron concentration in relation to systemic iron status and disease severity in non‐ischaemic heart failure with reduced ejection fraction	27
Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high‐risk acute heart failure patients	26
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities	26
Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis	26
Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial	26
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry	26
Worsening renal function in acute heart failure in the context of diuretic response	26
Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF	26
Use of biomarkers to diagnose and manage cardiac amyloidosis	26
Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata	26
Gut dysbiosis and heart failure: navigating the universe within	26
Excess out‐of‐hospital deaths during the COVID‐19 outbreak: evidence of pulmonary embolism as a main determinant	26
The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease	25
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index	25
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial	25
Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double‐blind, pla	25
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of	25
Epicardial fat in heart failure with reduced versus preserved ejection fraction	25
Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry	25
Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials	25
Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF‐1/CXCR4 signalling pat	25
Nutritional status in tricuspid regurgitation: implications of transcatheter repair	25
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF	25
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care	25
Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map	25
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT	24
B‐type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure	24
European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the	24
COVID‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology	24
Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial	24
Frequency, trends and institutional variation in 30‐day all‐cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand	24
The HFA‐PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction	24
Myocardial work and vascular dysfunction are partially improved at 12 months after COVID‐19 infection	24
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart fai	23
Predictors of left ventricular remodelling in patients with dilated cardiomyopathy – a cardiovascular magnetic resonance study	23
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of th	23
Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and	23
Prevention of heart failure events with sodium–glucose co‐transporter 2 inhibitors across a spectrum of cardio‐renal‐metabolic risk	23
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis	22
Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double‐blind, randomized, placebo‐controll	22
Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry	22
The burden of non‐cardiac comorbidities and association with clinical outcomes in an acute heart failure trial – insights from ASCEND‐HF	22
Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction	22
A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure	22
Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR<	22
Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T	22
Ischaemic cardiomyopathy. Pathophysiological insights, diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology	22
Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction	22
Myocardial dysfunction in long‐term breast cancer survivors treated at ages 40–50 years	22
Heart failure after treatment for breast cancer	22
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial	22
Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study	21
Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction	21
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial	21
Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non‐sudden cardiac death in myocardial infarction survivors with heart	21
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF	21
Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction	21
National trends in heart failure mortality in men and women, United Kingdom, 2000–2017	21
Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial	21
Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM‐HF trial	21
Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiolo	21
Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure	21
Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real‐world multicentre experience	20
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF	20
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced	20
Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX‐AHF‐2 trial	20
Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid‐range ejection fraction	20
Association between beta‐blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score‐matched analysis from the Swedish Heart Failure Reg	20
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	20
Impact of aspirin on takotsubo syndrome: a propensity score‐based analysis of the InterTAK Registry	20
Effects of hyperkalaemia and non‐adherence to renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity‐matched study	20
Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire	20
Effects of serelaxin in patients admitted for acute heart failure: a meta‐analysis	19
Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans	19
Association between systolic ejection time and outcomes in heart failure by ejection fraction	19
Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets	19
Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the VIP‐HF study	19
Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?	19
The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach	19
In‐hospital initiation of quadruple medical therapy for heart failure: making the post‐discharge vulnerable phase far less vulnerable	19
Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document	19
Impact of left atrial diameter on outcome in patients undergoing edge‐to‐edge mitral valve repair: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) regist	19
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial	19
Systemic embolism in amyloid transthyretin cardiomyopathy	19
Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction	19
The Heart Failure Association Atlas: rationale, objectives, and methods	19
Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan	18
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial	18
Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1‐year results from the CHOICE‐MI registry	18
Heart failure with preserved ejection fraction according to the HFA‐PEFF score in COVID‐19 patients: clinical correlates and echocardiographic findings	18
A randomized clinical trial on the short‐term effects of 12‐week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results fr	18
Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18	18
Short‐term prognostic implications of serum and urine neutrophil gelatinase‐associated lipocalin in acute heart failure: findings from the AKINESIS study	18
Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials	18
Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction	18
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial	18
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF	18
Is acute heart failure a distinctive disorder? An analysis from BIOSTAT‐CHF	17
Heart failure in Norway, 2000–2014: analysing incident, total and readmission rates using data from the Cardiovascular Disease in Norway (CVDNOR) Project	17
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction	17
Value of the HFA‐PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis	17
Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia	17
Sex and central obesity in heart failure with preserved ejection fraction	17
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF	17
Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non‐randomized, open‐label, proof‐of‐concept study	17
Contributions of cardiac dysfunction and volume status to central haemodynamics in chronic heart failure	17
Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) tri	17
Incidence and risk factors for pacemaker implantation in light‐chain and transthyretin cardiac amyloidosis	17
Viral presence‐guided immunomodulation in lymphocytic myocarditis: an update	17
Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction	17
Head‐to‐head comparison of contemporary heart failure risk scores	17
Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause – the Cardiogenic Shock Score	17
Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF	17
Effects of an outpatient intervention comprising nurse‐led non‐invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET study):	17
Type 2 diabetes increases the long‐term risk of heart failure and mortality in patients with atrial fibrillation	17
Change in ejection fraction and long‐term mortality in adults referred for echocardiography	17
Randomized trial of a left ventricular assist device as destination therapy versus guideline‐directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evalu	16
Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy	16
A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction	16

Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock	16
Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis	16
Peripheral and pulmonary effects of inorganic nitrite during exercise in heart failure with preserved ejection fraction	16
Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements (SCREAM) project	16
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinica	16
Pharmacotherapy for heart failure with reduced ejection fraction and health‐related quality of life: a systematic review and meta‐analysis	16
One‐year mortality after implantable cardioverter‐defibrillator placement within the Veterans Affairs Health System	16
Long‐term effects of Na + /Ca 2+ exchanger inhibition with ORM‐11035 improves cardiac function and remodelling without lowering bl	16
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis	15
Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure	15
Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis	15
Post‐discharge arrhythmic risk stratification of patients with acute myocarditis and life‐threatening ventricular tachyarrhythmias	15
Viral genome search in myocardium of patients with fulminant myocarditis	15
Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study	15
Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	15
Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity	15
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced	15
Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the	15
Heart failure treatment up‐titration and outcome and age: an analysis of BIOSTAT‐CHF	15
Time to end the war on cell therapy	15
Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15‐year prospective longitudinal trajectories in survivors	15
Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohort	15
Experience of remote cardiac care during the COVID‐19 pandemic: the V‐LAP™ device in advanced heart failure	15
Cardiovascular and non‐cardiovascular death distinction: the utility of troponin beyond N‐terminal pro‐B‐type natriuretic peptide. Findings from the BIOSTAT‐CHF study	15
Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction	15
Central role of left atrial dynamics in limiting exercise cardiac output increase and oxygen uptake in heart failure: insights by cardiopulmonary imaging	15
Clinical inertia and medical therapy for heart failure: the unintended harms of ‘first, do no harm’	15
Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME‐CHF trial	15
Cardiac output improvement by pecavaptan: a novel dual‐acting vasopressin V1a/V2 receptor antagonist in experimental heart failure	15
Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea	14
Practical outpatient management of worsening chronic heart failure	14
Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an ISHLT Mechanically Assisted Circulatory Support (IMACS) Registry analysi	14
Relationship between body mass index, cardiovascular biomarkers and incident heart failure	14
Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA‐VO2): a randomized clinical trial	14
Left ventricular systolic ejection time is an independent predictor of all‐cause mortality in heart failure with reduced ejection fraction	14
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial	14
Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis	14
Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study	14
Long‐term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand	14
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial	14
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis	14
First‐in‐man case of non‐invasive proton radiotherapy for the treatment of refractory ventricular tachycardia in advanced heart failure	14
Guidance on the management of left ventricular assist device (LVAD) supported patients for the non‐LVAD specialist healthcare provider: executive summary	14
Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Gro	14
The consequences of the COVID‐19 pandemic for self‐care in patients supported with a left ventricular assist device	14
The significance of left ventricular ejection time in heart failure with reduced ejection fraction	14
Predictors of sudden cardiac death in high‐risk patients following a myocardial infarction	14
Sodium–glucose co‐transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism	14
Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction	13
Non‐adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography‐tandem mass spectrometry (results of a prospective multicentre	13
How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure	13
Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review	13
Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics	13
Quantified mitral regurgitation and left atrial function in heart failure with reduced ejection fraction: interplay and outcome implications	13
Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions	13
Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world	13
Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC	13
Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT‐HF registry	13
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome	13
Impact of recent heart failure hospitalization on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the PARTNER 2	13
Pulmonary artery pulsatility index predicts right ventricular myofilament dysfunction in advanced human heart failure	13
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study	13
Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta‐analysis	13
Prevalence and incidence of intra‐ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE	13
The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative	13
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multic	13
Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Fai	13
Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure	13
Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction	13
High selenium levels associate with reduced risk of mortality and new‐onset heart failure: data from PREVEND	13
Early and short‐term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD‐HF)	12
SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure	12
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis	12
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence	12
Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED‐HF	12
Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?	12
Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry	12
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium	12
Decongestion discriminates risk for one‐year mortality in patients with improving renal function in acute heart failure	12
Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment	12
Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone	12
Advanced cancer is also a heart failure syndrome: a hypothesis	12
Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials	12
Effect of patient‐centered transitional care services on patient‐reported outcomes in heart failure: sex‐specific analysis of the PACT‐HF randomized controlled trial	12
Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy	12
Biventricular pacemaker therapy improves exercise capacity in patients with non‐obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise	12
Angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin‐co	12